CD274 and esophageal squamous cell carcinoma: However, several large randomized controlled trials on advanced ESCC have shown similar efficacy benefits from immune combination therapy across different PD-L1 expression subgroups.11,29,30 PD-L1 testing is currently not routine in China for patients with ESCC before the application of immunotherapy.